Abstract
The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Current Diabetes Reviews
Title:Prediction and Diagnosis of Post Transplant Diabetes
Volume: 11 Issue: 3
Author(s): Christopher J. Yates and Solomon J. Cohney
Affiliation:
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Abstract: The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Export Options
About this article
Cite this article as:
Yates J. Christopher and Cohney J. Solomon, Prediction and Diagnosis of Post Transplant Diabetes, Current Diabetes Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573399811999150316105553
DOI https://dx.doi.org/10.2174/1573399811999150316105553 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews Melatonin Synthetic Analogs as Nitric Oxide Synthase Inhibitors
Mini-Reviews in Medicinal Chemistry Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Role of Neurotrophins in Spinal Plasticity and Locomotion
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Astrocytes Pathology in ALS: A Potential Therapeutic Target?
Current Pharmaceutical Design Patent Selections
Recent Patents on Food, Nutrition & Agriculture Patient, System and Clinician Level Interventions to Address Disparities in Diabetes Care
Current Diabetes Reviews Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology An Update in the Management of Obesity: The Weight of CNS Targets
Recent Patents on CNS Drug Discovery (Discontinued)